MedPath

Comparison of Pressure Support and Pressure Control Ventilation in Chronic Respiratory Failure

Phase 4
Conditions
COPD
Chest Wall Disease
Neuromuscular Disease
Obesity Hypoventilation
Interventions
Other: Pressure support ventilation
Other: Pressure control ventilation
Registration Number
NCT00994552
Lead Sponsor
Guy's and St Thomas' NHS Foundation Trust
Brief Summary

This study is looking at whether there is a difference in outcomes using two different types of breathing support in those patients who have chronic respiratory failure (patients who under-breathe).

There is little data to demonstrate which mode of ventilation is better in terms of physiological outcomes and outcome data relating to patient symptoms.

We hypothesize that one type of breathing support: pressure support ventilation would be more comfortable for patients as it more closely matches a patient's own respiratory pattern and and so leads to improved adherence and consequent improvement in quality of life.

Patients with respiratory failure will be randomly assigned to receive either pressure support ventilation or pressure control ventilation for the first 6 weeks and then cross-over to receive the mode not previously used for a further 6 weeks. They will have baseline data recorded and then be followed up after each 6 week block.

Detailed Description

Not available

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
20
Inclusion Criteria
  • Patients with chest wall deformity, neuromuscular disease or obesity hypoventilation syndrome with an FEV1/FVC ratio of >70% and VC <50% predicted or patients with COPD with a FEV1/FVC ratio of <70% an FEV1 <50% predicted

  • Stable

    • pH >7.35
    • ESS <18
    • Symptomatically stable with clinical resolution of intercurrent infection: normal C reactive protein, white cell count and afebrile
  • Daytime symptoms compatible with nocturnal hypoventilation i.e. poor sleep, morning headache, daytime somnolence, shortness of breath

  • Arterial carbon dioxide partial pressure (PaCO2) > 6.0kPa during day with evidence of nocturnal hypoventilation (TcCO2 >7.5KPa or a rise in TcCO2 of >1 KPa)

  • No prior domiciliary ventilation use

  • Patients with COPD must be established on optimal medical treatment prior to enrolment

Exclusion Criteria
  • Psychological, social or geographical situation that would impair compliance with the schedule
  • Patients who have underlying malignancy or severe cardiac dysfunction (ejection fraction <40%)
  • Complex OSA

Study & Design

Study Type
INTERVENTIONAL
Study Design
CROSSOVER
Arm && Interventions
GroupInterventionDescription
Pressure support ventilationPressure support ventilationPressure support ventilation
Pressure control ventilationPressure control ventilationPressure control ventilation
Primary Outcome Measures
NameTimeMethod
Adherence to ventilation6 and 12 weeks
Secondary Outcome Measures
NameTimeMethod
Sleep fragmentation as assessed by actigraphy2 week perids from 4 and 10 weeks
Patient ventilator synchrony as measured by number of ineffective efforts6 and 12 weeks
Spirometry: forced expiratory volume in 1s and forced vital capacity6 and 12 weeks
Respiratory muscle strength: maximum inspiratory pressure, maximum expiratory pressure and sniff nasal pressure6 and 12 weeks
Arterial blood gases6 and 12 weeks
Health related quality of life as measured by CRQ and SRI6 and 12 weeks
Breathlessness (MRC dyspnoea score)6 and 12 weeks
Assessment of daytime vigilance and fatigue by the Epworth sleepiness score,Oxford sleep resistance test and the fatigue severity score.6 and 12 weeks
Sleep comfort as assessed by a visual analogue scale6 and 12 weeks

Trial Locations

Locations (1)

Guy's and St Thomas' NHS Foundation Trust

🇬🇧

London, United Kingdom

© Copyright 2025. All Rights Reserved by MedPath